Share on

Global Cardiac Marker Testing Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Type, Product, Disease, Testing & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 4803
Pages: 185
Formats: report pdf report excel report power bi report ppt

Cardiac Marker Testing Market Size (2022 to 2027)

The global cardiac marker testing market size was valued at USD 3.27 billion in 2022 and to grow USD 5 billion by 2027. This market is showcasing a CAGR of 8.89% from 2022 to 2027.

Cardiac markers are used in the treatment and risk stratification of patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers. These biomarkers can be used to detect a variety of heart disorders, including acute coronary syndrome, cardiac ischemia, and conditions involving obstructed blood flow to the heart. Physicians perform several cardiac marker tests over several hours to keep track of the blood sugar increase and determine the severity of a heart attack.


Y-O-Y growth in the aging population, growing funds by various organizations to encourage the experiments and clinical trials in marker testing for examining the novel markers of the heart are the factors that propel the global cardiac marker testing market growth.

Increasing incidences of heart-related diseases and spending a significant amount on R&D activities are fuelling the market demand. The demand is expected to develop as people become more aware of the importance of early diagnosis and the growing need to prevent cardiac disorders like heart failure, heart attack, ACS, and others. Increased coronary disease prevalence, an aging population, more clinical trials for cardiac biomarker detection, and increased support from public-private organizations for cardiac biomarker studies drive the cardiac marker testing market.

Additionally, Growth in point-of-care testing and growing demand for the latest treatment procedures are the factors that are accelerating the market. Also, increasing awareness over the benefits of early diagnosis and preventing heart diseases like heart attacks are driving the market growth.


Unfavorable reimbursements policies and stringent rules and regulations by the government are the factors that are hampering the global cardiac marker testing market growth. The cardiac markers are not used for diagnosing the myocardial blood supply to the heart or the tissue region that causes death. Problems related to storage and preservation of sample collection and amount paid in the cause of suffering are the factors that restrain the growth. Factors like correct and early outcomes and cardiac POC testing are the factors that drive the market growth.

COVID-19 impact on the global cardiac marker testing market:

The highly infectious extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which has resulted in a global outbreak. The cardiac marker testing market has also experienced short-term negative growth, which can be due to factors like a more than fifty percent decrease in the number of patients with cardiovascular diseases and those diagnosed with myocardial infarction. Traditional biomarkers of heart failure, such as cardiac markers and B-type natriuretic peptides (BNP), are increased in patients with COVID-19 due to the pandemic outbreak of the SARS-CoV-2 virus and novel coronavirus disease 2019 (COVID-19). All areas of cardiology service provision, including outpatient hospitals, investigations, treatments, and cardiology community services, including cardiac rehabilitation, experienced significant reductions. COVID-19 has several effects on the cardiovascular system. Inflammation, multi-organ interaction, and evidence of heart stress and disease describe COVID-19, a systemic infection. COVID-19 patients with chronic or coronary heart disease have a higher percentage of abnormal cardiac markers and a higher mortality and ICU admission rate. In COVID-19 patients with or without pre-existing coronary artery disease, BNP, along with hs-TNI, - HBDH, CK-MB, and LDH, acts as a prognostic biomarker. By considering all these factors, Cardiac Marker Testing Market has moderate growth during this pandemic and is expected to have more demand in coming years.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Type, Product, Disease, Testing, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global cardiac marker testing market has been segmented and sub-segmented based on type, product, disease, testing, and region.

Cardiac Marker Testing Market - By Type:

  • Troponin I & T
  • CK-MB
  • Myoglobin
  • BNP
  • HsCRP

Based on type, the troponin cardiac biomarkers segment is forecasted to lead the global cardiac marker testing market during the forecast period due to its efficiency and accuracy in test results to diagnose cardiovascular disorders.

Cardiac Marker Testing Market – By Product:

  • Reagent
  • Instrument
    • Chemiluminescence
    • Immunofluorescence
    • Immunochromatography
    • ELISA

Cardiac Marker Testing Market – By Disease:

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure

Based on disease, myocardial infarction is one of the fastest-growing segments, credited to its increase in the rate of sedentary lifestyle among individuals, alcohol consumption, smoking, and unhealthy food habits, resulting in obesity.

Cardiac Marker Testing Market – By Testing:

  • Lab
  • POC

Based on testing, the laboratory testing segment is predicted to lead the global cardiac marker testing market. The point-of-care testing segment offers the highest growth rate in this market segment. It can be credited to the availability of easy-to-use kits in ambulances, and affordability for patients at the point-of-care diagnostic tool reduces expenditure on hospitals, thereby increasing the adoption rate of new diagnostic tools.

Cardiac Marker Testing Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American market is predicted to hold the largest share of the global cardiac marker testing market, followed by Europe during the forecast period. Because of the prevalence of cardiovascular disorders, the public and private investments, NIH funding for creating novel cardiac biomarkers, and the growing geriatric population, North America is expected to be the largest market. Furthermore, government and research institute measures to fight critical cardiac diseases and an increase in R&D activities related to cardiac biomarkers, driving market growth in North America.

However, the Asia-Pacific market is to register the highest growth due to emerging markets, including India and China, which have become attractive destinations for companies engaged in the development and marketing of cardiac biomarkers. The rising prevalence and incidence of cardiovascular diseases are among the major driving factors for the market growth in China and India. Increased healthcare spending by a larger population base, transformation of healthcare facilities, and the penetration of clinical laboratory technology is driving the Asia-Pacific market. Along with this, demand in Asia-Pacific is expected to expand due to an increase in research-based pharmaceutical companies' interest in developing novel biomarkers and increasing the number of patients suffering from cardiovascular diseases.


Some of the notable companies dominating the global cardiac marker testing market profiled in the report are Getinge Group, Medtronic PLC, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd and Guangzhou Wondfo Biotech Co. Ltd.


  • On May 06, 2019, Abbott stated that it is launching the next generation smartphone connectable Confirm RX, which FDA and CE Mark accept for implantable continuous cardiac monitoring. It is for quick and early diagnosis of remote monitoring heart problems.
  • On October 06, 2016, The U.S. FDA gave 510(K) acceptance for Xprecia Stride Coagulation Strider, a hand-held device that was developed by Siemens for monitoring oral anticoagulation therapy. It is to collect blood samples which is the most occurring test that inhibits the formation of clots in high risk of developing them in people, those with heart valve replacement surgery, and with heart defects.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample